

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/91780 A1

(51) International Patent Classification⁷: A61K 38/00, C07K 2/00, 5/00, 7/00

(21) International Application Number: PCT/US01/16654

(22) International Filing Date: 23 May 2001 (23.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/207,654 26 May 2000 (26.05.2000) US

(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; US Route 202, Raritan, NJ 08869 (US).

(72) Inventors: SMITH-SWINTOSKY, Virginia; 3163 Line Lexington Road, Hatfield, PA 19440 (US). RENZI, Michael; 485 Oak Drive, Harleysville, PA 19438 (US). PLATA-SALAMAN, Carlos; 1313 Squire Drive, Ambler, PA 19002 (US). JOLLIFFE, Linda; 16 Davenport Way, Belle Mead, NJ 08501 (US). FARRELL, Francis; 4934 Julie Court, Doylestown, PA 18890 (US). JOHNSON, Dana, L.; 1343 Lonely Cottage Road, Upper Black Eddy, PA 19872 (US).

(74) Agent: WALLEN, John, W., III; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933-7003 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SF, SG, SI, SK, SI, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/91780 A1

(54) Title: NEUROPROTECTIVE PEPTIDES

(57) Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

BEST AVAILABLE COPY

NEUROPROTECTIVE PEPTIDES

CROSS-REFERENCE TO RELATED APPLICATION

5 This application claims the benefit of United States Provisional Application Serial No. 60/207654, filed May 26, 2000.

FIELD OF THE INVENTION

10 The present invention is directed to methods of treating diseases and conditions involving the nervous system by administration of compositions having the therapeutic activity of human erythropoietin. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. The 15 present invention also provides improved therapeutic regimens wherein the therapeutic agent is administered at concentrations below those required to stimulate hematopoiesis.

BACKGROUND OF THE INVENTION

20 Erythropoietin (EPO) is a glycoprotein hormone produced by the kidney in response to tissue hypoxia that stimulates red blood cell production in the bone marrow. The gene for erythropoietin has been cloned and expressed in Chinese hamster ovary (CHO) cells as described in United States Patent No. 4,703,008. Recombinant human erythropoietin (r-HuEPO or Epoetin alfa) has an amino acid sequence identical to that of human urinary 25 erythropoietin, and the two are indistinguishable in chemical, physical and immunological tests. Recombinant human erythropoietin acts by increasing the number of cells capable of differentiating into mature erythrocytes, triggering their differentiation and augmenting hemoglobin synthesis in developing erythroblasts (Krantz SB. *Blood* (1991) 77: 419-434, Beckman BS, Mason-Garcia M. *The Faseb Journal* (1991) 5: 2958-2964).

Epoetin alfa has been well tolerated in studies conducted to date. Hypertensive encephalopathy and seizures have occasionally been described in dialysis patients treated with Epoetin alfa, particularly during the early phase of therapy when hematocrit is rising. (Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. *New Engl J Med* (1987) 316: 73-78, 5 Winearls CG, Oliver DO, Pippard MJ, et al. *Lancet* (1986) 2 (8517): 1175-1177). Such reports became more rare as experience of use of the compound developed. Occasionally, cancer patients treated with Epoetin alfa have experienced an increase in blood pressure associated with a significant increase in hematocrit. The risk, however, appears substantially lower than in chronic renal failure patients.

10

No antibody titers against Epoetin alfa could be demonstrated and confirmed in subjects treated with Epoetin alfa for up to 2 years, indicating the absence of immunological sensitivity to Epoetin alfa. Skin rashes and urticaria have been observed rarely and when reported have been mild and transient in nature, but these events suggest allergic hypersensitivity to some 15 components of the Epoetin alfa formulation.

Epoetin alfa is approved for sale in many countries for the treatment of anemia in chronic renal failure (dialysis and predialysis), anemia in zidovudine treated HIV positive patients (US), anemia in cancer patients receiving platinum-based chemotherapy, as a facilitator of 20 autologous blood pre-donation, and as a peri-surgical adjuvant to reduce the likelihood of requiring allogeneic blood transfusions in patients undergoing orthopedic surgery.

EPO influences neuronal stem cells, likely during embryonic development, and possibly during *in vitro* experiments of differentiation. (Juul et al *Pediatr Dev Pathol* (1999) 25 2(2) 148 – 158. Juul et al *Pediatr Res* (1998) 43(1) 40 – 49.) Further, neonates and infants that suffer CNS injury via hypoxia, meningitis, and intraventricular hemorrhage, show an EPO induced neuroprotective effect (Juul et al *Ped Res* (1999) 46(5) 543 – 547.)

EPO helps prevent apoptosis of neural tissue in cases of injury that create hypoxia. 30 This may be the result of EPO produced locally by astrocytes (Morishita et al *Neuroscience* (1996) 76(1) 105 – 116). Neuroprotection has been demonstrated in gerbil hippocampal and

rat cerebrocortical tissue (Sakanaka et al *PNAS* (1998) 95(8) 4635 – 4640. Sadamoto et al *Biochem Biophys Res Commun* (1998) 253(1) 26 – 32).

5 EPO induces biological effects of PC12 cells, including changes in Ca^{2+} , changes in membrane potential, and promotion of neuronal survival. This has been interpreted that EPO can stimulate neural function and viability (Koshimura et al *J. Neurochem* (1999) 72(6) 2565-2572. Tabria et al *Int J Dev Neurosci* (1995) 13(3/4) 241 – 252.).

10 O'Brien et al propose that a 17 amino acid peptide sequence of EPO can act through the EPO –R (Erythropoietin receptor) to induce biological activity in NS20Y, SK-N-MC, and PC12 cells, which includes sprouting, differentiation and neuroprotection. Curiously this peptide does not promote proliferation of hematologic cells, thus it appears inactive in cell lines well understood for their sensitivity to EPO activity. (Campana et al *Int J Mol Med* (1998) 1(1) 235 – 241 and United States Patent No.'s 5,700,909, issued on 12/23/1999, 15 5,571,787, issued on 11/5/1996, 5,714,459, issued on 2/3/1998, and 5,696,080, issued on 12/9/1997, all to O'Brien et al.)

20 EPO may influence neuronal stem cell commitment to drive differentiation of neurons as opposed to astrocytes or oligodendrocytes. This is compared to a similar activity of EPO, where it functions to drive commitment of hematopoietic stem cells to produce red blood cells (RBCs). There is an apparent relationship between CNS hypoxic injury, resulting in the production of EPO from astrocytes that commits neuronal stem cells to differentiate into neurons, while simultaneously acting as a neuroprotective function for existing neurons. (WIPO publication number WO99/21966, published on 5/6/1999, Weiss et al.)

25

SUMMARY OF THE INVENTION

30 The present invention is directed to methods of treating diseases and conditions involving the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin.

In a first embodiment, the present invention is directed to a method for treating a patient having a disorder characterized by neurotoxicity, neurodegeneration or neurological damage, comprising administering to said patient a therapeutically effective amount of a peptide comprising one or more monomeric peptides of 8 to about 40 amino acids in length
5 that bind to EPO receptor, each monomeric peptide comprising a sequence of amino acids $X_4X_5X_aX_bX_6X_cX_dX_7$ (SEQ ID NO: 47), wherein

X_a is G or A;

10 X_b is P or A;

X_c is T or A;

X_d is selected from W, A, and F;

15 X_4 is selected from R, H, Y, L, and W, or X_4 is nonexistent;

X_5 is selected from F, M, and I;

20 X_6 is independently selected from the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; and

X_7 is selected from D, V, E, I, and L.

25 In particular, said sequence is $X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 1), wherein

X_3 is selected from C, E, A, α -amino- γ -bromobutyric acid, and homocysteine (Hoc);
and

30 X_8 is selected from C, K, A, α -amino- γ -bromobutyric acid, and homocysteine (Hoc).

In a second embodiment, the present invention is directed to peptides which behave as cell-surface receptor agonists and antagonists, as well as dimers and multimers of such peptides which exhibit binding and signal initiation of growth factor-type receptors. In one embodiment, the present invention provides peptides which behave as 5 EPO agonists. These peptides may be dimers or multimers of such peptides, preferably 14 to about 20 residues in length, comprising a core amino acid sequence of $X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 1) wherein each amino acid is indicated by standard one letter abbreviation; X_3 can be C, E, A, α -amino- γ -bromobutyric acid, or Hoc, where Hoc is homocysteine; X_4 can be R, H, Y, L, or W, or X_4 is nonexistent; X_5 can be M, F, or I; 10 X_6 is independently any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; X_7 can be D, E, I, L, or V; and X_8 can be C, K, A, α -amino- γ -bromobutyric acid, or Hoc, where Hoc is homocysteine.

Preferably, the monomeric peptide unit of the dimer or multimer comprises a core 15 sequence of amino acids $YX_2X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 2), wherein each of X_2 and X_6 is independently any one of the 20 genetically coded L-amino acids; X_3 is C; and X_8 is C.

Preferably, the monomeric peptide unit of the dimer comprises a core sequence of 20 amino acids $X_1YX_2X_3X_4X_5GPX_6TWX_7X_8X_9X_{10}X_{11}$ (SEQ ID NO: 3), wherein each of X_1 , X_2 , X_6 , X_9 , X_{10} , and X_{11} is independently selected from the 20 genetically coded L-amino acids. Particularly, X_3 can be C, E, A; X_4 can be R, H, or Y, or X_4 is nonexistent; X_5 can be M, F, or I; X_7 can be D or V; and X_8 can be C, K, or A.

In a more preferred embodiment, both X_3 and X_8 are C and thus, the monomeric 25 peptide unit of the dimer comprises a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 4). Particularly, the monomeric peptide unit comprises a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 5), where X_4 can be R or H; X_5 can be F or M; X_6 can be I, L, T, M, or V; X_7 is D or V; X_9 can be G, K, L, Q, R, S, or T; and X_{10} can be A, G, P, R, or Y. More particularly, the 30 monomeric peptide unit of the dimer will comprise a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 6), where X_1 can be D, E, L, N, S,

T, or V; X₂ can be A, H, K, L, M, S, or T; X₄ is R or H; X₉ can be K, R, S, or T; and X₁₀ is P.

5 Preferably, the monomeric peptide unit of the dimer will comprise a core sequence of amino acids X₁ YX₂ CX₄ X₅ GPX₆ TWX₇ CX₉ X₁₀ X₁₁ (SEQ ID NO: 6), where X₁ can be D, E, L, N, S, T, or V; X₂ can be A, H, K, L, M, S, or T; X₄ is R or H; X₉ can be K, R, S, or T; and X₁₀ is P.

Particularly preferred monomeric peptide units of the dimers include:

10

GGLYLCRFGPVTWDCGYKGG (SEQ ID NO:7);
GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8);
GGDYHCRMGPLTWVCKPLGG (SEQ ID NO:9);
VGNYMCHFGPITWVCRPGGG (SEQ ID NO:10);
15 GGVYACRMGPITWVCSPPLGG (SEQ ID NO:11);
VGNYMAHMGPITWVCRPGGG (SEQ ID NO:12);
GGTYSCHFGPLTWVCKPQ (aka EMP-16) (SEQ ID NO:13);
GGLYACHMGPMTWVCQPLRG (aka EMP-36) (SEQ ID NO:14);
TIAQYICYMGPETWECRSPSKA (aka EMP-38) (SEQ ID NO:15);
20 YSCHFGPLTWVCK (aka EMP-20) (SEQ ID NO:16);
YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17);
SCHFGPLTWVCK (aka EMP-24) (SEQ ID NO:18);
GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19);
GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20);
25 GGTYSCFGPLTWVCKPQGG (aka EMP-27) (SEQ ID NO:21);
TYSCHFGPLTWVCKPQGG (aka EMP-17) (SEQ ID NO:22);
TYSCHFGPLTWVCKPQ (aka EMP-18) (SEQ ID NO:23);
YSCHFGPLTWVCKP (aka EMP-19) (SEQ ID NO:24);
YSCHFGPLTWVC (aka EMP-21) (SEQ ID NO:25);
30 YSCHFGALTWVCK (aka EMP-22) (SEQ ID NO:26);
GGCRIGPITWVC CGG (aka EMP-25) (SEQ ID NO:27);
HFGPLTWV (aka EMP-26) (SEQ ID NO:28);

	GGTTSCHFGPLTWVCKPQGG	(aka EMP-7) (SEQ ID NO:29);
	GGTFSCHFGPLTWVCKPQGG	(aka EMP-8) (SEQ ID NO:30);
	GGTYSCHFGALTWVCKPQGG	(aka EMP-10) (SEQ ID NO:31);
	GGTYSCHFGPATWVCKPQGG	(aka EMP-11) (SEQ ID NO:32);
5	GGTYSCHFGPLAWVCKPQGG	(aka EMP-12) (SEQ ID NO:33);
	GGTYSCHFGPLTAVCKPQGG	(aka EMP-13) (SEQ ID NO:34);
	GGTYSCHFGPLTFVCKPQGG	(aka EMP-14) (SEQ ID NO:35);
	GGTYSCHFGPLTWVCKAQGG	(aka EMP-15) (SEQ ID NO:36);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-28, X = D-Tyr) (SEQ ID NO:37);
10	GGTXSCHFGPLTWVCKPQGG	(aka EMP-29, X = <i>p</i> -NO ₂ -Phe) (SEQ ID NO:38);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-30, X = <i>p</i> -NH ₂ -Phe) (SEQ ID NO:39);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-31, X = <i>p</i> -F-Phe) (SEQ ID NO:40);
15	GGTXSCHFGPLTWVCKPQGG	(aka EMP-32, X = <i>p</i> -I-Phe) (SEQ ID NO:41);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-33, X = 3,5-dibromo-Tyr) (SEQ ID NO:42);
	Ac-GGTYSCHFGPLTWVCKPQGG	(aka EMP-34) (SEQ ID NO:43);
	GGLYACHMGPMTWVCQPLGG	(aka EMP-35) (SEQ ID NO:44);
20	LGRKYSCHFGPLTWVCQPAKKD	(aka EMP-37) (SEQ ID NO:45); and
	GGTYSEHFGPLTWVKKPQGG	(aka EMP-39) (SEQ ID NO:46).

Preferably, monomeric peptide units of the dimers include:

25	GGTYSCHFGPLTWVCKPQGG	(aka EMP-1) (SEQ ID NO:8);
	GGTASCHFGPLTWVCKPQGG	(aka EMP-6) (SEQ ID NO:19);
	GGTYSCHFAPLTWVCKPQGG	(aka EMP-9) (SEQ ID NO:20); and
	YCHFGPLTWVC	(aka EMP-23) (SEQ ID NO:17).

In accordance with the present invention the monomeric units of the dimers can be the same or different.

5 In a preferred embodiment polyethylene glycol (PEG) may be employed as a linker to form the dimeric peptides of the present invention through a covalent bond.

In another embodiment, the present invention is directed to pharmaceutical compositions comprising at least one peptide of the invention and a pharmaceutical carrier to be used in a method of treating or preventing neurotoxicity.

10

In a further embodiment, the present invention provides a method for therapeutically treating a mammal having a disease or condition resulting from a neurotoxic or neurodegenerative or neuro-damaging event by administration of at least one of the peptides of the present invention.

15

In a still further embodiment, a method for therapeutically treating a mammal having a neurotoxic, neuro-damaging or neurodegenerative condition which may be modulated by EPO by using at least one of the peptides of the present invention is provided.

20

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 Panel A and Panel B show that EPO receptor is expressed in rat hippocampal and cortical cultures.

Figure 2 shows that EPO receptor is expressed in neuronal cell lines: PC12 and SK-25 N-MC cells.

30 Figure 3 shows EPO induced gene expression in PC12 cells. (Top) Total RNA isolated from PC-12 cells treated with 1 nm EPO for 24 hr was subject to RT-PCR to quantify the changes in gene expression of specific BCL family members. Pre-treatment with EPO resulted in a 6 fold increase in the expression of the anti-apoptotic gene BCL_{XL} and a greater than 5 fold decrease in the expression of the pro-apoptotic Bak. These results are consistent with the gene chip results suggesting a possible mechanism for EPO's protective effects. (Bottom) Agarose gels showing RT-PCR products representing the regulation of

Bcl_{XL} and Bak. m – markers, 1 – RT-PCR negative control, lane 2 – No Treatment, lane 3 – 50 ng/ml NGF, lane 4 – EPO 1 nm.

Figure 4 shows that rhEPO protects rat cerebral cortical neurons against glutamate toxicity.

5 Figure 5 shows that rhEPO protects rat PC12 cells against glutamate-induced cell death. 7 day cultures of PC-12 cells were treated with erythropoietin for 24 hours before being exposed to a toxic concentration of glutamate (200 μ m). Cultures were allowed to recover for 24 hours and cell survival was determined using a Trypan Blue exclusion assay. 1 to 10 pm Erythropoietin given 24 hours prior to a 15 minute exposure to glutamate 10 significantly increased cell survival ($p<.001$, student's t-test. The protective activity of EPO decreased at higher doses.

15 Figure 6 shows that rhEPO protects rat PC12 cells against NGF withdrawal-induced cell death. Cultures of PC-12 cells were grown in the presence of NGF for 7 days and then treated with EPO for 24 hours before they were switched to media without NGF. Cell survival was determined by counting the number of viable cells immediately following the removal of NGF and comparing it to the number of viable cells at 12 hr, 24 hr, 48 hr and 72 hr following growth factor withdrawal. Cell viability was determined based on morphological characteristics including phase brightness, presence of axons and absence of membrane blebbing. Treatment with EPO increased the number of viable cells at each time point 20 following growth factor withdrawal with an optimum concentration of 10 pm.

Figure 7 shows that rhEPO promotes neurite outgrowth in rat cerebral cultures.

Figure 8 shows that rhEPO promotes neurite outgrowth in rat hippocampal cultures.

Figure 9 shows that EMP-1 promotes neurite outgrowth in rat cerebral cortical cultures.

25 Figure 10 shows that EMP-1 promotes neurite outgrowth in rat hippocampal cultures.

Figure 11 shows that EMP-6 promotes neurite outgrowth in rat cerebral cortical cultures.

Figure 12 shows that EMP-6 promotes neurite outgrowth in rat hippocampal cultures.

30 Figure 13 shows that EMP-9 promotes neurite outgrowth in rat cerebral cortical cultures.

Figure 14 shows that EMP-9 promotes neurite outgrowth in rat hippocampal cultures.

Figure 15 shows that EMP-23 promotes neurite outgrowth in rat cerebral cortical cultures.

Figure 16 shows that EMP-23 promotes neurite outgrowth in rat hippocampal cultures.

5 Figure 17 shows that EMP-27 promotes neurite outgrowth in rat cerebral cortical cultures.

Figure 18 shows that EMP-27 promotes neurite outgrowth in rat hippocampal cultures.

10 Figure 19 shows that EPO protects against ischemic injury: study I continuous iv infusion via osmotic mini-pump.

Figure 20 shows plasma determinations for study I.

Figure 21 shows that EPO does not protect against ischemic injury: study II single iv bolus dose.

Figure 22 shows plasma determinations for study II.

15 Figure 23 shows that EPO protects against ischemic injury: study III repeat iv bolus dosing.

Figure 24 shows plasma determinations: study III.

DETAILED DESCRIPTION

20

"Erythropoietin" (EPO) used herein includes those peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity (for example, hematopoietic and neurological activities) of human erythropoietin or only certain biological activities (for example, hematopoietic or neurological activities only) of erythropoietin, as 25 well as erythropoietin analogs, erythropoietin isoforms, erythropoietin mimetics, erythropoietin fragments, hybrid erythropoietin proteins, fusion proteins, oligomers and multimers of the above, homologues of the above, glycosylation pattern variants of the above, and muteins of the above, regardless of the biological activity of same, and further regardless of the method of synthesis or manufacture thereof including, but not limited to, 30 recombinant, whether produced from cDNA or genomic DNA, synthetic, transgenic, and gene activated methods. Specific examples of erythropoietin include, Epoetin alfa (EPREX®, ERYPO®, PROCRIT®), NEORECORMON, Novel erythropoiesis stimulating protein (NESP

or ARANESP, a hyperglycosylated analog of recombinant human erythropoietin (Epoetin) described in European patent application EP640619), human erythropoietin analog – human serum albumin fusion proteins such as those described in the international patent application WO 99/66054, erythropoietin mutants such as those described in the international patent 5 application WO 99/38890, erythropoietin omega, which may be produced from an Apa I restriction fragment of the human erythropoietin gene described in United States Patent No. 5,688,679, altered glycosylated human erythropoietin such as those described in the international patent application WO 99/11781, PEG conjugated erythropoietin analogs such as those described in WO 98/05363 or United States Patent No. 5,643,575. Specific 10 examples of cell lines modified for expression of endogenous human erythropoietin are described in international patent applications WO 99/05268 and WO 94/12650. The generally preferred form of EPO is purified, recombinant human EPO (rhEPO), currently formulated and distributed under the trademarks of EPREX®, ERYPO®, or PROCRIT®.

15 The abbreviation “EMP” as used herein refers to peptide mimetics of EPO, particularly certain peptides described in United States Patent No.’s 5,767,078 and 5,773,569.

Following is a list of amino acid abbreviations used in the present specification for various peptides. The individual amino acid residues are identified according to a single letter and three letter code that is readily known and used by those of ordinary skill in the art.

20

	<u>AMINO ACID</u>	<u>ABBREVIATIONS</u>	
		3-Letter	1-Letter
	alanine	ala	A
	valine	val	V
25	leucine	leu	L
	isoleucine	ile	I
	proline	pro	P
	phenylalanine	phe	F
	tryptophan	trp	W
30	methionine	met	M
	glycine	gly	G

	serine	ser	S
	threonine	thr	T
	cysteine	cys	C
	tyrosine	tyr	Y
5	asparagine	asn	N
	glutamine	gln	Q
	aspartic acid	asp	D
	glutamic acid	glu	E
	lysine	lys	K
10	arginine	arg	R
	histidine	his	H

In a first embodiment, the present invention is directed to methods of treating neuronal cells with a pharmaceutical composition comprising a therapeutically active peptide 15 that behaves as cell-surface receptor agonists as well as dimers and multimers of such peptides that exhibit binding and signal initiation of growth factor-type receptors. In one embodiment, the present invention provides peptides that behave as EPO agonists. Particularly, these peptides may be dimers or multimers that have two 'monomeric' peptide units of 8 to 40 or more amino acids, preferably 14 to about 20 residues in length, comprising 20 a core amino acid sequence of $X_3 X_4 X_5 GPX_6 TWX_7 X_8$ (SEQ ID NO: 1) where each amino acid is indicated by standard one letter abbreviation; X_3 can be C, E, A, α -amino- γ -bromobutyric acid, or Hoc, where Hoc is homocysteine; X_4 can be R, H, Y, L, or W, or X_4 is nonexistent; X_5 can be M, F, or I; X_6 is independently any one of the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; X_7 can be D, E, I, L, or V; and X_8 can be C, 25 K, A, α -amino- γ -bromobutyric acid, or Hoc, where Hoc is homocysteine, provided that either X_3 or X_8 is C or Hoc. Preferably, the monomeric peptide unit of the dimer or multimer comprises a core sequence $YX_2X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 2) where each amino acid is indicated by standard one letter abbreviation; each X_1 , X_2 , X_6 , X_9 , X_{10} , and X_{11} is independently selected from the 20 genetically coded L-amino acids; X_3 can be C, E, A, α -amino- γ -bromobutyric acid, or Hoc, where Hoc is homocysteine; X_4 can be R, H, Y, L, or W, 30 or X_4 is nonexistent; X_5 can be M, F, or I; X_7 can be D, E, I, L, or V; and X_8 can be C, K, A,

α -aminobutyric acid, or Hoc, where Hoc is homocysteine. More preferably, either X_3 or X_8 is C or Hoc.

5 Preferably, the monomeric peptide unit of the dimer or multimer comprises a core sequence of amino acids $YX_2X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 2), wherein each of X_2 and X_6 is independently any one of the 20 genetically coded L-amino acids; X_3 is C; and X_8 is C.

10 Preferably, the monomeric peptide unit of the dimer comprises a core sequence of amino acids $X_1YX_2X_3X_4X_5GPX_6TWX_7X_8X_9X_{10}X_{11}$ (SEQ ID NO: 3), wherein each of X_1 , X_2 , X_6 , X_9 , X_{10} , and X_{11} is independently selected from the 20 genetically coded L-amino acids. Particularly, X_3 can be C, E, A; X_4 can be R, H, or Y, or X_4 is nonexistent; X_5 can be M, F, or I; X_7 can be D or V; and X_8 can be C, K, or A.

15 In a more preferred embodiment, both X_3 and X_8 are C and thus, the monomeric peptide unit of the dimer comprises a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 4). Particularly, the monomeric peptide unit comprises a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 5), where X_4 can be R or H; X_5 can be F or M; X_6 can be I, L, T, M, or V; X_7 is D or V; X_9 can be G, K, L, Q, R, S, or T; and X_{10} can be A, G, P, R, or Y. More particularly, the 20 monomeric peptide unit of the dimer will comprise a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 6), where X_1 can be D, E, L, N, S, T, or V; X_2 can be A, H, K, L, M, S, or T; X_4 is R or H; X_9 can be K, R, S, or T; and X_{10} is P.

25 Preferably, the monomeric peptide unit of the dimer will comprise a core sequence of amino acids $X_1YX_2CX_4X_5GPX_6TWX_7CX_9X_{10}X_{11}$ (SEQ ID NO: 6), where X_1 can be D, E, L, N, S, T, or V; X_2 can be A, H, K, L, M, S, or T; X_4 is R or H; X_9 can be K, R, S, or T; and X_{10} is P.

Particularly preferred monomeric peptide units of the dimers include:

	GGLYLCRFGPVTWDCGYKGG	(SEQ ID NO:7);
	GGTYSCHFGPLTWVCKPQGG	(aka EMP-1) (SEQ ID NO:8);
5	GGDYHCRMGPLTWVCKPLGG	(SEQ ID NO:9);
	VGNYMCHFGPITWVCRPGGG	(SEQ ID NO:10);
	GGVYACRMGPITWVCSPLGG	(SEQ ID NO:11);
	VGNYMAHMGPITWVCRPGG	(SEQ ID NO:12);
	GGTYSCHFGPLTWVCKPQ	(aka EMP-16) (SEQ ID NO:13);
10	GGLYACHMGPMTWVCQPLRG	(aka EMP-36) (SEQ ID NO:14);
	TIAQYICYMGPETWECRSPSKA	(aka EMP-38) (SEQ ID NO:15);
	YSCHFGPLTWVCK	(aka EMP-20 (SEQ ID NO:16);
	YCHFGPLTWVC	(aka EMP-23) (SEQ ID NO:17);
	SCHFGPLTWVCK	(aka EMP-24) (SEQ ID NO:18);
15	GGTASCHFGPLTWVCKPQGG	(aka EMP-6) (SEQ ID NO:19);
	GGTYSCHFAPLTWVCKPQGG	(aka EMP-9) (SEQ ID NO:20);
	GGTYSCFGPLTWVCKPQGG	(aka EMP-27) (SEQ ID NO:21);
	TYSCHFGPLTWVCKPQGG	(aka EMP-17) (SEQ ID NO:22);
	TYSCHFGPLTWVCKPQ	(aka EMP-18) (SEQ ID NO:23);
20	YSCHFGPLTWVCKP	(aka EMP-19) (SEQ ID NO:24);
	YSCHFGPLTWVC	(aka EMP-21) (SEQ ID NO:25);
	YSCHFGALTWVCK	(aka EMP-22) (SEQ ID NO:26);
	GGCRIGPITWVCGG	(aka EMP-25) (SEQ ID NO:27);
	HFGPLTWV	(aka EMP-26) (SEQ ID NO:28);
25	GGTSCHFGPLTWVCKPQGG	(aka EMP-7) (SEQ ID NO:29);
	GGTFSCHFGPLTWVCKPQGG	(aka EMP-8) (SEQ ID NO:30);
	GGTYSCHFGALTWVCKPQGG	(aka EMP-10) (SEQ ID NO:31);
	GGTYSCHFGPATWVCKPQGG	(aka EMP-11) (SEQ ID NO:32);
	GGTYSCHFGPLAWVCKPQGG	(aka EMP-12) (SEQ ID NO:33);
30	GGTYSCHFGPLTAVCKPQGG	(aka EMP-13) (SEQ ID NO:34);
	GGTYSCHFGPLTFVCKPQGG	(aka EMP-14) (SEQ ID NO:35);
	GGTYSCHFGPLTWVCKAQGG	(aka EMP-15) (SEQ ID NO:36);

GGTXSCHFGPLTWVCKPQGG (aka EMP-28, X = D-Tyr) (SEQ ID NO:37);
GGTXSCHFGPLTWVCKPQGG (aka EMP-29, X = *p*-NO₂-Phe)
(SEQ ID NO:38);
GGTXSCHFGPLTWVCKPQGG (aka EMP-30, X = *p*-NH₂-Phe)
(SEQ ID NO:39);
5 GGTXSCHFGPLTWVCKPQGG (aka EMP-31, X = *p*-F-Phe) (SEQ ID NO:40);
GGTXSCHFGPLTWVCKPQGG (aka EMP-32, X = *p*-I-Phe) (SEQ ID NO:41);
GGTXSCHFGPLTWVCKPQGG (aka EMP-33, X = 3,5-dibromo-Tyr)
(SEQ ID NO:42);
10 Ac-GGTYSCHFGPLTWVCKPQGG (aka EMP-34) (SEQ ID NO:43);
GGLYACHMGPMTWVCQPLGG (aka EMP-35) (SEQ ID NO:44);
LGRKYSCHFGPLTWVCQPAKKD (aka EMP-37) (SEQ ID NO:45); and
GGTYSEHFGPLTWVKKPQGG (aka EMP-39) (SEQ ID NO:46).

15 Most preferably, monomeric peptide units of the dimers include:

GGTYSCHFGPLTWVCKPQGG (aka EMP-1) (SEQ ID NO:8);
GGTASCHFGPLTWVCKPQGG (aka EMP-6) (SEQ ID NO:19);
GGTYSCHFAPLTWVCKPQGG (aka EMP-9) (SEQ ID NO:20); and
YCHFGPLTWVC (aka EMP-23) (SEQ ID NO:17).

20 EPO is administered by any suitable means as appropriate for the particular patient being treated, as would be apparent to one skilled in the art. The phrase "therapeutically effective" as used herein will vary from patient-to-patient, and depending on the particular range of biological activities possessed by the EPO molecule being administered. Typically, for EPO
25 having hematopoietic activity, a therapeutically effective amount will be from about 1 to 500 I.U./kg body weight and more preferably from 50 to 300 I.U./kg body weight especially when erythropoietin is administered via subcutaneously. For EPO molecules not possessing hematopoietic activity the therapeutically effective dose may be more or less than an EPO molecule having hematopoietic activity. The preferred methods of administration are intravenous (iv) and subcutaneous (sc), with subcutaneous being generally preferred. Hematopoietically active EPO is administered within the range of about 50 – 1000 U/kg per dose, one to five times per week. In another embodiment, the EPO composition is administrated

directly to the nervous system. This administration route includes, but is not limited to, the intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and/or peri-spinal routes of administration, which can employ intracranial and intravertebral needles, and catheters with or without pump devices. Infusion doses can range, for example, 5 from about 1.0 to 50,000 U/kg/min of EPO composition over a period ranging from several minutes to several days. Hematopoietically active EPO administration is delayed or withheld if the patient, male or female, exhibits a hemoglobin level in excess of about 15 g/dL.

The present invention provides in one embodiment a method to treat acute and 10 chronic neurodegenerative disorders comprising administration of EPO or analogs thereof. Acute neurodegenerative disorders include, but are not limited to, various types of acute neurodegenerative disorders associated with neuronal cell death or compromise including cerebrovascular insufficiency, focal or diffuse brain trauma, diffuse brain damage, and spinal cord injury. Examples of acute neurodegenerative disorders are: cerebral ischemia or 15 infarction including embolic occlusion and thrombotic occlusion, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest, as well as intracranial hemorrhage of any type (such as epidural, subdural, subarachnoid and intracerebral), and intracranial and intravertebral lesions (such as contusion, penetration, shear, compression and laceration), and whiplash shaken infant syndrome. Chronic neurodegenerative disorders that 20 can be treated with one or more methods of the present invention include, but are not limited to, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), chronic epileptic conditions associated with neurodegeneration, motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, 25 ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies (including multiple system atrophy), primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease / spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's 30 disease), primary lateral sclerosis, familial spastic paraparesis, Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal

leukoencephalopathy, familial dysautonomia (Riley-Day syndrome), and prion diseases (including, but not limited to Creutzfeldt-Jakob, Gerstmann-Sträussler-Scheinker disease, Kuru and fatal familial insomnia).

5 Because of the combination of neuroprotection and neurite outgrowth induced by rhEPO, other clinical conditions can be treated with one or more methods of the present invention include treating and / or preventing the neurological (including, but not limited to, cognitive) and psychiatric (including, but not limited to, psychopathology, depression, or anxiety), manifestations associated with peripheral diseases including, but not limited to,
10 EPO deficiency (e.g., renal disease), blood loss of any kind (including, but not limited to, hemodialysis, peritoneal dialysis, diagnostic sampling, occult gastrointestinal bleeding), renal failure and end-stage renal disease, renal transplantation, and other conditions associated with anemia and neurological and neuropsychiatric manifestations, including, but not limited to, hematological and non-hematological malignancies / cancer, symptoms or complications in
15 patients receiving chemotherapy (including, but not limited to, cisplatin) and other drugs (including, but not limited to, zidovudine), other hematological disorders (including, but not limited to, sickle cell anemia and thalassemia), inflammatory and infectious disorders (including, but not limited to, human immunodeficiency viral infections), chronic systemic autoimmune diseases (including, but not limited to, systemic lupus erythematosus), Henoch
20 Schonlein Purpura, and hemolytic uremic syndrome. Also included in the present invention are the treatment and / or prevention of neurological and neuropsychiatric manifestations resulting from chemical, toxic, infectious and radiation injury of the nervous system and as a result of prematurity, as well as the treatment and / or prevention of neurological and neuropsychiatric consequences of encephalopathies including, but not limited to, those of
25 anoxic-ischemia, hepatic, glycemic, uremic, electrolyte and endocrine origin.

Also, because of the combination of neuroprotection and neurite outgrowth induced by rhEPO, this molecule can also be applicable for the treatment and / or prevention of plexopathies (including plexus palsies), multifocal neuropathies, sensory neuropathies, motor
30 neuropathies, sensory-motor neuropathies, infections neuropathies, autonomic neuropathies, sensory-autonomic neuropathies, demyelinating neuropathies (including, but not limited to, Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy),

other inflammatory and immune neuropathies, neuropathies induced by drugs, neuropathies induced by pharmacological treatments, neuropathies induced by toxins, traumatic neuropathies (including, but not limited to, compression, crush, laceration and segmentation neuropathies), metabolic neuropathies, endocrine and paraneoplastic neuropathies, and other 5 neuropathies such as Charcot-Marie-Tooth disease (type 1a, 1b, 2, 4a,1-X linked), Friedreich's ataxia, metachromatic leukodystrophy, Refsum's disease, adrenomyeloneuropathy, Ataxia-telangiectasia, Déjerine-Sottas neuropathy (types A and B), Lambert-Eaton syndrome, and disorders of the cranial nerves.

10 The following examples illustrate the present invention without, however, limiting the same thereto.

EXAMPLE 1

rhEPO is expressed in primary rat neuronal cultures and in neuronal cell lines

15 *Primary Neuronal Cell Culture*

Dissociated hippocampal and cortical cell cultures were established from embryonic day 18 rat fetuses as previously described (Mattson et al., 1994). Briefly, fetuses were removed via cesarean section from pregnant moms (Sprague-Dawley) anesthetized with halothane according to the AVMA Panel on Euthanasia. Pups were decapitated and the 20 brains were removed and placed in HEPES-buffered Hank's Balanced Salt solution (HBSS; Gibco). The hippocampi and cortices were dissected out and pooled according to tissue-type. Tissue was trypsinized for 15 min (1mg/ml trypsin-HBSS; Worthington), rinsed with fresh HBSS, incubated in trypsin inhibitor (1mg/ml; Sigma) for 5 min, rinsed again with fresh 25 HBSS and then triturated in 1ml fresh HBSS with a fire-polished glass pipette. Dissociated cells were seeded at 30,000 cells/well onto poly-D-lysine coated 96-well plates (Collaborative BioScience). Each well contained 100µl of Eagle's Minimal Essential Media (MEM; Gibco) supplemented with 26mM NaHCO₃ (Sigma), 56mM glucose (Sigma), 15mM KCl (Sigma), 1mM sodium pyruvate (Sigma), 1.1mM L-glutamine (Sigma), 10% (v/v) heat-inactivated fetal bovine serum (Hyclone), and 0.001% gentamicin sulfate (Sigma) (pH 7.4). 30 Cells were allowed to attach for 24h in a humidified 37°C 5% CO₂ incubator before experimental treatment. The culture media was aspirated and exchanged with fresh media every three days.

Immunocytochemistry

Parallel hippocampal and cortical cultures were treated as described above and were processed for immunocytochemistry (ICC) as described previously (Smith-Swintosky et al., 1997). Briefly, cells were plated onto four-chamber poly-D-lysine 5 coated glass slides (LabTek, Napersville, IL). On the seventh day in culture, the culture media was removed and the cells were washed once with Dulbecco's phosphate buffered saline (DPBS; Sigma) and then fixed with 10% phosphate-buffered formalin for 15min at room temperature. After fixation, the cultures were rinsed with DPBS and placed in blocking serum for 10min (normal horse serum; 1:50 dilution in DPBS; Vector Labs, 10 Burlingame, CA). Cultures were rinsed again and then incubated for 30min in an anti-mouse monoclonal antibody specific to the EPO receptor (EBP-7); 1:75 dilution in antibody diluent (Zymed, South San Francisco, CA). Cultures were rinsed several times with DPBS, then exposed to biotinylated secondary antibody for 30min (Vector Labs). Cultures were rinsed a final time and then incubated for 30min in avidin-biotinylated 15 horseradish peroxidase complex (mouse IgG ABC kit, Vector Labs). The presence of the primary antibody was detected using 3'3-diaminobenzidine tetrahydrochloride (DAB, Biomeda, Foster City, CA) - two exposures for 5min each. Cells were then counterstained with hematoxylin, dehydrated, cleared, coverslipped and photographed under an Olympus BX-2 light microscope.

20

Results

Robust staining for EPO receptor was observed in both neurons and glia within hippocampal and cortical cultures (Figure 1a and Figure 1b). EPO receptor expression levels appear to increase with time in culture.

25

Discussion

These results show that EPO plays a role in early development of the nervous system, particularly the hippocampus and cerebral cortex.

30 *Immunohistochemistry of neuronal cell lines*

The neuronal cell lines PC-12, derived from a pheochromocytoma of the rat adrenal gland (Greene and Tischler, 1976), and SK-N-MC, obtained from a neuroepithelioma of a

brain of human origin (Spengler et al., 1973), were used: PC-12 cells can be reversibly induced to the neuronal phenotype in the presence of nerve growth factor (NGF). PC-12 cells were grown on poly-D-Lysine coated tissue culture dishes in DMEM containing 10% horse serum and 5% FBS and in the presence of 0.1 μ g/ml NGF for 7 days to induce the neuronal phenotype. SK-N-MC cells were cultured in minimal essential media supplemented with 1.0 mM Sodium pyruvate, 1.5 g/L sodium bicarbonate, 2mM glutamine and 10% FBS for 4 days. PC-12 and SK-N-MC cells were cultured in a 96 well plate from Greiner, conducive for microscopy. On the day of the experiment cells were fixed in 10% Formalin containing 10% sucrose and incubated in blocking buffer (40 mM Tris HCL, Ph 8.0, 27mM NaCl, and 0.2%Tween 20). Receptors for erythropoietin were detected by incubating the cells with a rabbit polyclonal, anti-erythropoietin receptor antibody (C-20 from Santa Cruz) and a FITC conjugated secondary antibody. Labeled cells were visualized using a fluorescent microscope (ATTO).

15 *Results*

A polyclonal antibody against the erythropoietin receptor labeled both SK-N-MC and PC-12 cells as seen in Figure 2 (right panels). All SK-N-MC cells visible at low magnification appeared to be labeled with the antibody. The majority of PC-12 cells that were detectable were labeled with the anti-erythropoietin receptor antibody. A few intact PC-12 cells that retained a characteristic neuronal phenotype in this preparation showed staining throughout the axonal process as well as in the cell body. Secondary antibody alone did not label either cell type (Figure 2, left panels).

25 Therefore, these results demonstrate that these cell lines, SK-N-MC cells from a human neuroepithelioma and PC-12 cells from a rat pheochromocytoma, express the erythropoietin receptor. These cell lines are therefore responsive to erythropoietin and can provide a good system to study the effects of erythropoietin on neurons.

EXAMPLE 2**EPO induced gene expression in PC12 cells***Cell Culture*

5 PC-12 cells (from a rat Pheochromocytoma) were cultured on poly-D-Lysine coated tissue culture plastic in DMEM containing 10 % FBS and 5% Horse serum. To induce the neuronal phenotype in PC-12 cells, serum was removed and the cells were treated with NGF (50 ng/ml). Cells were grown for 7 days in the presence of the NGF then used for experiments.

10

EPO Treatment and RNA isolation

PC-12 cells were cultured as described in Example 1 in a 10 cm poly-D-lysine coated tissue culture dish. Cells were incubated in the presence of 1U/ml of EPO for 24 hr. Total RNA was then isolated using a Qiagen RNAeasy mini prep kit and used for RT-PCR.

15

Quantitative RT-PCR

Real time reverse transcription and PCR were performed in a single reaction using a light cycler and an RNA amplification kit from Roche Molecular Biochemicals. RNA was quantitated and added in equal amounts to reaction mix that includes the dsDNA specific dye 20 SYBR green I. Specific PCR reaction products are quantitated by detecting the amount of fluorescence in the reaction at each PCR cycle. Final analysis was performed using the data analysis software included with the light cycler instrument.

Summary

25 Pre-treatment of PC-12 cells with EPO (1U/ml) for 24 hr resulted in significant changes in the gene expression of the bcl-2 family members *bcl_{XL}* and *bak* as seen in Figure 3. Cells treated with EPO showed a 6-fold increase in the expression of the anti-apoptotic gene, *bcl_{XL}*, and a 5-fold decrease in the expression of the pro-apoptotic gene, *bak*. EPO has been shown previously to increase the survival of red blood cell progenitor cells by 30 increasing *bcl_{XL}* expression (Silva et al., 1996). These results show that EPO uses a similar mechanism to protect neurons from undergoing apoptosis in response to injury. The

regulation of *bak* shows that EPO can effect the expression of additional genes to elicit this effect.

EXAMPLE 3

5

rhEPO neuroprotection and neurite outgrowth effects on rat hippocampal and cortical cells and PC12 cells

Primary Neuronal Cell Culture

Dissociated hippocampal and cortical cell cultures were established from embryonic 10 day 18 rat fetuses as previously described (Mattson et al., 1994). Briefly, fetuses were removed via cesarean section from pregnant moms (Sprague-Dawley) anesthetized with halothane according to the AVMA Panel on Euthanasia. Pups were decapitated and the brains were removed and placed in HEPES-buffered Hank's Balanced Salt solution (HBSS; Gibco). The hippocampi and cortices were dissected out and pooled according to tissue-type. 15 Tissue was trypsinized for 15 min (1mg/ml trypsin-HBSS; Worthington), rinsed with fresh HBSS, incubated in trypsin inhibitor (1mg/ml; Sigma) for 5 min, rinsed again with fresh HBSS and then triturated in 1ml fresh HBSS with a fire-polished glass pipette. Dissociated cells were seeded at 30,000 cells/well onto poly-D-lysine coated 96-well plates (Collaborative BioScience). Each well contained 100 μ l of Eagle's Minimal Essential Media 20 (MEM; Gibco) supplemented with 26mM NaHCO₃ (Sigma), 56mM glucose (Sigma), 15mM KCl (Sigma), 1mM sodium pyruvate (Sigma), 1.1mM L-glutamine (Sigma), 10% (v/v) heat-inactivated fetal bovine serum (Hyclone), and 0.001% gentamicin sulfate (Sigma) (pH 7.4). Cells were allowed to attach for 24h in a humidified 37°C 5% CO₂ incubator before experimental treatment. The culture media was aspirated and exchanged with fresh media 25 every three days.

Glutamate Toxicity Assay

Cortical cells were seeded at 200,000 cells/dish onto polyethylenimine-coated 35mm culture dishes. Each dish contained 1.5ml MEM supplemented as described above. On the 30 seventh day in culture, four fields per pre-marked dish were visualized with a Nikon Diaphot inverted microscope (10x magnification) and photographed prior to experimental treatment. Immediately following, the cultures were treated with vehicle or recombinant human

erythropoietin (*rhEPO*; lot #41C514; 50 μ M stock in 0.2M citrate, 0.585g.L NaCl diluted to appropriate concentrations in Dulbecco's phosphate buffered saline (DPBS; Sigma) + 0.1% bovine serum albumin (BSA; Sigma)). Twenty-four hours later the cultures were treated with 100 μ M glutamate (Sigma). Twenty-four hours post-glutamate, the four fields from each 5 dish were photographed again. Cell survival was measured by counting viable cells in each field pre- and post-experimental treatment. Neurons were considered viable if they had neurites that were uniform in diameter and smooth in appearance, and somata that were smooth and round to oval in shape. Data were expressed as percent of control (vehicle; mean \pm SD).

10

PC12 Cell Culture

PC-12 cells (from a rat Pheochromocytoma) were cultured on poly-D-Lysine coated tissue culture plastic in DMEM containing 10 % FBS and 5% Horse serum. To induce the neuronal phenotype in PC-12 cells, serum was removed and the cells were treated with NGF 15 (50 ng/ml). Cells were grown for 7 days in the presence of the NGF then used for experiments.

Glutamate Toxicity

PC-12 cells were cultured as described above. 24 hr prior to insult, cells were treated 20 with rhEPO at concentrations ranging from 1 pm to 1 nm. On the day of the experiment, cells were exposed to 200 μ M glutamate for 30 min. Cells were then washed 2 times with fresh media to remove the glutamate and cultured in fresh media containing NGF but no EPO. After 24 hr cells were assayed for viability using a trypan blue exclusion assay. Briefly, media was removed and the cells were incubated in 0.4% Trypan Blue for 5 min. Cells were 25 then washed gently with PBS, then fixed with 10% formalin. Cell viability was determined by counting the total number of cells vs. the number of trypan blue positive (dead) cells.

NGF withdrawal

PC-12 cells were cultured as described above in a 96 well poly-d-lysine coated 30 multi-well plate and treated with rhEPO (1 pm to 10 nm) for 24 hr prior to NGF withdrawal. On the day of the experiment the cells were washed with buffer 3 times to

remove NGF and then cultured in fresh media without NGF. Immediately following NGF washout cells were counted (t=0) to determine the number of living cells. Cell viability was based on morphological characteristics including phase brightness, presence of axons, and absence of blebbing. Cell counts were performed at 12 hr, 24 hr, 48 hr and 5 72 hr and the number of viable cells were scored.

Neurite Outgrowth Assay

Twenty-four hours after plating, cultures were treated with vehicle (PBS+0.1% BSA), 100ng of various growth factors (brain derived neurotrophic factor (BDNF; Promega), glial-derived neurotrophic factor (GDNF; Promega), nerve growth factor (NGF; Boehringer Mannheim), basic fibroblast growth factor (bFGF; Boehringer Mannheim), insulin-like growth factor -1 (IGF-1; Boehringer Mannheim), neurotrophin-3 (NT3; Calbiochem), neurotrophin-4 (NT4; Calbiochem), ciliary neurotrophic factor (CNTF; Calbiochem), epidermal growth factor (EGF; Calbiochem), vascular endothelial growth factor (VEGF; 10 Calbiochem)), or rhEPO (prepared same as above; 10fM – 10nM)). Each treatment condition was run in quadruplicate or octuplicate. On the third day in culture, the media was aspirated off and replaced with fresh media and test compound. At one week in culture, the cells were fixed with 10% phosphate-buffered formalin for 15min, then rinsed with DPBS (Sigma) and placed in blocking serum for 30 min (horse serum; 1:50 dilution in DPBS; Vector Labs). 15 Cultures were rinsed again with DPBS and then incubated in primary antibody for 2 hr (microtubule-associated protein-2 (MAP-2) is a selective marker for dendritic processes; anti-mouse monoclonal (Chemicon); 1:1000 dilution of MAP-2 in antibody diluent (Zymed)). Negative control wells were incubated in antibody diluent alone. Background signal was determined by blank wells (cell-free) incubated with or without antibody. 20 Cultures were rinsed again with DPBS and then placed in fluorescein for 1 hr (FITC; anti-mouse IgG; rat adsorbed; 1:50 dilution in DPBS; Vector Labs). Cultures were rinsed a final time with DPBS and then the plates were read on a Cytofluor 4000 fluorescence plate reader. Neurite outgrowth was expressed as percent change from control (vehicle; mean fluorescence 25 ± SD).

Results

Neuroprotection study with primary neuronal cultures: Pretreatment of cultures with rhEPO for 24h prior to glutamate administration resulted in a significant increase in neuronal survival (Figure 4). Cell survival was maximally increased approximately 200% over 5 parallel cultures treated with glutamate alone. The neuroprotective effect of rhEPO was concentration-dependent, with the greatest effects observed at pM concentrations in which cell survival was greater than or equal to vehicle (no glutamate) treated cultures.

Neuroprotection study with PC12 cells: Pre-treatment with EPO resulted in a 10 significant decrease in cell death induced by both glutamate toxicity and growth factor withdrawal in PC-12 cells (Figures 5 and 6). The peak concentration for the neuroprotective effect in both experiments was 10 pm. The dose response curve for the neuroprotective effect of EPO was bi-phasic with the ability of EPO to protect cells against cytotoxicity decreasing at concentrations above 10 pm, with no significant effect at 1 nm. These results suggest that 15 EPO is able to prevent an apoptotic response in neurons exposed to a variety of cytotoxic insults

Neurite outgrowth study with primary neuronal cultures: Cultures treated with rhEPO resulted in a significant increase in neurite outgrowth as measured by MAP2-FITC 20 immunofluorescence. The neurite outgrowth promoting effect was concentration dependent with maximal activity observed at pM levels (Figures 7 and 8). The results indicate that rhEPO treatment induced a larger outgrowth response in the hippocampal cultures (12-44% over control) than in the cortical cultures (15-29% over control). A comparison between rhEPO and known growth factors indicates that they exhibit regional differences in their 25 neurite outgrowth promoting abilities. rhEPO's ability to increase neurite outgrowth in cortical cultures is greater than or equal to that of known growth factors. This observation is compelling and important since few factors have such effects on cortical cells. On the other hand, many growth factors exert strong outgrowth responses in the hippocampus (38-86% over control). Compared to such growth factors, rhEPO showed moderate yet robust 30 outgrowth promoting activity; however, its activity was superior to several growth factors including BDNF, NGF and VEGF.

Discussion

The neuroprotection studies confirmed previous evidence that rhEPO is protective at pM concentrations against glutamate toxicity and serum withdrawal in vitro.

5 Surprisingly we discovered that rhEPO promotes neurite outgrowth in primary mammalian neural cells. The effect was robust for hippocampal and cortical cells. The effect was potent with efficacy observed at sub-picomolar concentrations, far more potent than any previous EPO related observation. Moreover, in cerebral cortical neurons, which respond to few growth factors, rhEPO was superior in inducing neurite outgrowth relative to
10 the majority of known growth factors.

From a therapeutic perspective, the observation that rhEPO promotes neuroprotection and neurite outgrowth in cerebral cortical neurons is very important. During neurodegeneration, neural cells can be in different stages of the process. Some may be
15 stressed, others experience significant neurite retraction and loss of synaptic input, and eventually all affected cells will succumb to death. A therapeutic agent that can intervene in this process at multiple levels can be of great benefit to the recovery of the neural cells and eventually neural function. The present data support that rhEPO accomplishes this task by protecting the cells, by enhancing their survival, by promoting re-establishment of synaptic
20 contacts and connections, and by stabilizing the neuronal and neural circuitry.

It should also be specified that the data are particularly important, considering that very few growth factors are effective in cerebral cortical neurons, and also that very few growth factors display the dual activity as neuroprotectants and promoters of neurite
25 outgrowth in cortical neurons. It is particularly relevant that this dual activity of rhEPO was observed at sub-picomolar / picomolar concentrations.

EXAMPLE 4**EPO MIMETIC PEPTIDES STIMULATE NEURITE OUTGROWTH**

Cell Culture

Dissociated hippocampal and cortical cell cultures were established from embryonic day 18 rat fetuses as previously described (Mattson et al., 1994). Briefly, fetuses were removed via cesarean section from pregnant moms (Sprague-Dawley) anesthetized with 5 halothane according to the AVMA Panel on Euthanasia. Pups were decapitated and the brains were removed and placed in HEPES-buffered Hank's Balanced Salt solution (HBSS; Gibco). The hippocampi and cortices were dissected out and pooled according to tissue-type. Tissue was trypsinized for 15 min (1mg/ml trypsin-HBSS; Worthington), rinsed with fresh 10 HBSS, incubated in trypsin inhibitor (1mg/ml; Sigma) for 5 min, rinsed again with fresh HBSS and then triturated in 1ml fresh HBSS with a fire-polished glass pipette. Dissociated cells were seeded at 30,000 cells/well onto poly-D-lysine coated 96-well plates (Collaborative BioScience). Each well contained 100µl of Eagle's Minimal Essential Media (MEM; Gibco) supplemented with 26mM NaHCO₃ (Sigma), 56mM glucose (Sigma), 15mM KCl (Sigma), 1mM sodium pyruvate (Sigma), 1.1mM L-glutamine (Sigma), 10% (v/v) heat-15 inactivated fetal bovine serum (Hyclone), and 0.001% gentamicin sulfate (Sigma) (pH 7.4). Cells were allowed to attach for 24h in a humidified 37°C 5% CO₂ incubator before experimental treatment. The culture media was aspirated and exchanged with fresh media every 3 days.

20 *Neurite Outgrowth Assay*

Twenty-four hours after plating, cultures were treated with vehicle (PBS+0.1% BSA), 100ng of various growth factors (brain derived neurotrophic factor (BDNF; Promega), glial-derived neurotrophic factor (GDNF; Promega), nerve growth factor (NGF; Boehringer Mannheim), basic fibroblast growth factor (bFGF; Boehringer Mannheim), insulin-like 25 growth factor -1 (IGF-1; Boehringer Mannheim), neurotrophin-3 (NT3; Calbiochem), neurotrophin-4 (NT4; Calbiochem), ciliary neurotrophic factor (CNTF; Calbiochem), epidermal growth factor (EGF; Calbiochem), vascular endothelial growth factor (VEGF; Calbiochem)), or Epo mimetic peptides (EMP1, EMP6, EMP9, EMP23 and EMP27; diluted in DPBS+0.1% BSA; 10fM – 10nM; Table 1). Each treatment condition was run in 30 quadruplicate. On the third day in culture, the media was aspirated off and replaced with fresh media and test compound. At one week in culture, the cells were fixed with 10%

phosphate-buffered formalin for 15min, then rinsed with DPBS (Sigma) and placed in blocking serum for 30 min (horse serum; 1:50 dilution in DPBS; Vector Labs). Cultures were rinsed again with DPBS and then incubated in primary antibody for 2 hr (microtubule-associated protein-2 (MAP-2) is a selective marker for dendritic processes; anti-mouse 5 monoclonal (Chemicon); 1:1000 dilution of MAP-2 in antibody diluent (Zymed)). Negative control wells were incubated in antibody diluent alone. Background signal was determined by blank wells (cell-free) incubated with or without antibody. Cultures were rinsed again with DPBS and then placed in fluorescein for 1 hr (FITC; anti-mouse IgG; rat adsorbed; 1:50 dilution in DPBS; Vector Labs). Cultures were rinsed a final time with DPBS and then the 10 plates were read on a Cytofluor 4000 fluorescence plate reader. Neurite outgrowth was expressed as percent change from control (vehicle; mean fluorescence \pm SEM).

Table 1: Erythropoietin Mimetic Peptides (EMP)

SEQ.ID.NO	Sequence name	Sequence
7	EMP-1	GGTYSCHFGPLTWVCKPQGG
19	EMP-6	GGTASCHFGPLTWVCKPQGG
20	EMP-9	GGTYSCHFAPLTWVCKPQGG
17	EMP-23	Y-CHFGPLTWVC
21	EMP-27	GGTYSC-FGPLTWVCKPQGG

Results

15 Neurite outgrowth study: Cultures treated with EMP's resulted in a significant increase in neurite outgrowth as measured by MAP2-FITC immunofluorescence. The neurite outgrowth promoting effect was concentration dependent with maximal activity observed at pM levels (Figures 9-18). The results indicate that EMP's displayed different activity profiles. At the concentrations tested, EMP-1 and 6 displayed typical bell-shaped dose- 20 response profiles in hippocampal cultures with peak activity observed between 30-300pM (83-117% increase over vehicle). EMP-9 and 27 exhibited a flat response profile in hippocampal cultures with peak activity observed at similar concentrations as EMP-1 and 6, but the amplitude of the response was greatly attenuated (29-32% increase over vehicle). EMP-23 had a modest response to EPO in hippocampal cultures with peak activity observed 25 between 30pM-1nM that led to a 43-46% increase over vehicle response. In the cortical

cultures, EMP-1, 9 and 27 exhibited response profiles similar to most known growth factors – a flat response overall with maximal activity occurring between 30-300pM reaching 32-40% above the vehicle response. EMP-6 and 23 displayed typical bell-shaped dose-response profiles with peak activity observed between 30-300pM resulting in a 68-87% increase in 5 outgrowth over vehicle response levels. Overall, EMP-6 promoted robust neurite outgrowth activity in both hippocampal and cortical cultures; whereas, EMP-1 showed selective effects in hippocampal cultures over cortical cultures and EMP-23 effects were greater in cortical cultures than hippocampal cells. EMP-9 and 27 neurite outgrowth responses were less impressive overall.

10

A comparison between the EMP's and known growth factors indicated that they exhibit regional differences in their neurite outgrowth promoting abilities. The EMP's ability to increase neurite outgrowth in cortical cultures was greater than or equal to that of known growth factors (Figure 9-18). This observation is compelling and important since few factors 15 have such effects on cortical cells. On the other hand, many growth factors exert strong outgrowth responses in the hippocampus (38-86% over control). Compared to such growth factors, the EMP's showed moderate yet robust outgrowth promoting activity; however, they displayed superior activity over BDNF, NGF and VEGF.

20 *Discussion*

EMP's promote neurite outgrowth in mammalian cells. The effect was robust for hippocampal and cortical cells. The neurite outgrowth promoting effect was superior to that of various growth factors. The effect was potent with efficacy observed at picomolar concentrations.

25

It should also be specified that the data are particularly important, considering that very few growth factors or mimetics are effective in cerebral cortical neurons in promoting neurite outgrowth. It is particularly relevant that this activity of the EMPs was observed at sub-picmolar / picomolar concentrations.

30

EXAMPLE 5**EPO protects against ischemic injury***Subjects*

5 Male spontaneous hypertensive rats (Charles River) weighing between 250-300g were weighed and then anesthetized with ketamine (100mg/ml)/xylazine (20mg/ml) cocktail (1.2ml/kg; i.p.). The level of anesthetic was assessed by corneal reflex (air puff to eye) and leg jerk in response to tail or foot pinch. Once the rat was anesthetized, it was placed on a small animal surgical board and restrained during the surgical procedure. The rat's body
10 temperature was monitored continuously with a rectal probe and maintained at 37°C with a homeostatic heating pad.

Experimental model of cerebral ischemia

Rats were rendered ischemic by tandem occlusion of the left common carotid artery
15 and the left middle cerebral artery for 2h followed by 22h of reperfusion using a modification of the technique described by Brint and co-workers (*J. Cereb Blood Flow Metab* 8:474-485, 1988). Specifically, the left CCA was isolated through an incision in the ventral surface of the neck. For isolation of the ipsilateral MCA, a second incision was made between the lateral canthus of the left eye and the corresponding external auditory canal to bare the
20 underlying skull. The MCA was exposed through a 5mm burrhole drilled 2-3mm rostral to the fusion of the zygomatic arch and the squamosal bone under direct visualization with a Zeiss operating microscope. The dura was opened with a sterile 26g needle and a platinum alloy wire (0.1mm diameter) was inserted beneath the MCA just superior to the inferior cortical vein. The MCA was temporarily occluded by elevation and compression of the vessel
25 across the alloy wire, as described by Aronowski and colleagues (*Stroke*, 25:2235-2240, 1994). Concurrently, the CCA was occluded with an aneurysm clip. The duration of occlusion of the CCA and the MCA was 2h. At the end of this period, the wire and the clip were carefully removed to allow reperfusion of the vessels and the incision area was sutured shut. The rat was placed in an isolation cage to recover before returning to his home cage. .

*Study Design*Study I: EPO and vehicle delivered via osmotic mini-pump

Twenty-hours prior to the onset of ischemia, an osmotic mini-pump (Model 1003D; Alza) filled with vehicle or EPO was placed between the scapula of the rat. A catheter attached to the pump was inserted and tethered within the right jugular vein for continuous infusion of drug at a rate of 1 μ l/hr. Rats were divided into five groups: (1) sham-operated vehicle-treated, (2) ischemic vehicle treated, (3) ischemic 1.32U/day EPO treated, (4) ischemic 132U/day EPO treated and (5) ischemic 1321U/day EPO treated. On Day Two, rats were rendered ischemic as described above. Twenty-two hours later, the rats were evaluated for behavioral performance, a blood sample was collected for terminal plasma levels of EPO and then the rat was euthanized, brain removed, sectioned and stained for histological analysis.

Study II: EPO and vehicle delivered as a single intravenous bolus injection

On Day One, the rats were rendered ischemic as described above. Rats were divided into four groups: (1) ischemic vehicle treated, (2) ischemic 1000U/kg EPO treated, (3) ischemic 2500U/kg EPO treated and (4) 5000U/kg EPO treated. Fifteen minutes post-occlusion, the rats received vehicle or EPO as an intravenous bolus injection. Twenty-two hours later, the rats were evaluated for behavioral performance, a blood sample was collected for terminal plasma levels of EPO and then the rat was euthanized, brain removed, sectioned and stained for histological analysis.

Study III: EPO and vehicle delivered as repeat intravenous bolus injections

On Day One, the rats were rendered ischemic as described above. Rats were divided into two groups: (1) ischemic vehicle treated and (2) ischemic 2500U/kg EPO treated. Drug was administered as an intravenous bolus at 15min, 2h, 4h and 6h post-occlusion for a total dose of 10,000U/kg. Twenty-two hours later, the rats were evaluated for behavioral performance, a blood sample was collected for terminal plasma levels of EPO and then the rat was euthanized, brain removed, sectioned and stained for histological analysis.

Outcome measures

Plasma Determinations: Blood samples were collected from each rat via the orbital sinus at the time of sacrifice. Plasma was separated out, frozen and analyzed by EPO ELISA for determination of plasma concentration (U/ml).

5

Infarct Volume: Brains were removed, blocked into 1mm slabs and stained with 2,3,5-triphenyl tetrazolium chloride dye (TTC; Sigma) for 15 min at room temperature. Stained sections were stored in 10% buffered formalin at 4oC. Sections were visualized by a Nikon SMZ-U microdissecting scope. Images of each brain section were captured with a 10 CCD camera and processed using Image Pro Phase III software in order to calculate infarct volume.

Results

Study I: EPO given at 132 or 1321U/day as a continuous infusion via osmotic mini-pump significantly reduced infarct volume (Figure 19). Plasma concentrations correlated 15 with the protective effect (Figure 20).

Study II: EPO given as a single iv bolus 15 min post-occlusion did not protect against ischemic damage in this model at 1000, 2500 or 5000U/kg (Figure 21). Plasma concentrations were low in each group (Figure 22).

20

Study III: EPO given as a repeat iv bolus of 2500U/kg at 15min, 2h, 4h and 6h post-occlusion led to a significant decrease in infarct volume (Figure 23). Plasma concentrations are presently being determined (Figure 24).

25 *Discussion*

Data support that continuous or repeat dosing with low to moderate concentrations of EPO can significantly reduce infarct volume in spontaneous hypertensive rats rendered ischemic via the transient tandem occlusion of the CCA and MCA. The results also support that there is a critical relationship between the amount and timing of EPO administration for 30 the protective effect to occur. Low doses of EPO given over an extended period of time can be more beneficial than high doses given the same way or as a single bolus infusion. This is

in agreement with the in vitro data indicating that EPO maximal protective effect is observed at low doses (pM) and actually loses efficacy at higher doses (μ M).

REFERENCES

Johnson, D.L., Farrell, F.X., Barbone, F.P., McMahon, F.J., Tullai, J., Hoey K., Wrighton, N.C., Livnah, O., Middleton, S.A., Loughney, D., Stura, E.A., Dower, W.J., Mulcahy, L.S.,
5 Wilson, I.A. & Jolliffe L.K., Identification of a 13 Amino Acid Peptide Mimetic of Erythropoietin and Description of Amino Acids Critical for the Mimetic Activity of EMP1, Biochemistry 37, 3699-3710 (1998).

Johnson, D.L., Farrell, F.X., Barbone, F.P., McMahon, F.P., Tullai, J., Kroon, D., Freedy, J.,
10 Zivin , R.A., Mulcahy, L.S., & Jolliffe, L.K. Amino Terminal Dimerization of an Erythropoietin Mimetic Peptide Results in Increased Erythropoietic Activity, Chemistry & Biology 4, 939-950 (1997).

Johnson, Dana L.; Zivin, Robert A. Agonist peptide dimers. US Patent No. 5,767,078
15

Campana, W.M., Misasi, R. and O'Brien, J.S. (1998) Identification of a neurotrophic sequence of erythropoietin. Inter. J. Mol. Med. 1:235-241.

Patent application WO 95/03821, O'Brien, J.S., Kishimoto, Y. and Altman, D.E. Title:
20 Prosaposin and cytokine-derived peptides as therapeutic agents.

Sadamoto, Y, Igase, K, Sakanaka, M., Sato, K, Otsuka, H., Sakaki, S., Masuda, S. and Sasaki, R. (1998). Erythropoietin prevent place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Comm. 253:26-32.
25

Tabira, T., Konishi, Y. and Gallyas, F. (1995). Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro. Int. J. Dev. Neurosci. 13:241-252.

30 Morishita, E., Masuda, S., Nagao, M., Yasuda, Y. and Sasaki, R. (1997). Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevent in vitro glutamate-induced neuronal death. Neurosci 76:105-116.

Sakanaka, M, Wen T-C, Matsuda, S, Masuda, S., Morishita, E., Nagao, M., and Sasaki, R. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. 95:4635-4640.

5

Marti, H.H., Gassman, M., Wenger, R.H., Kvietikova, I., Morganti-Kossmann, M.C., Kossmann, T., Trentz, O., and Bauer, C. (1997) Detection of erythropoietin in human liquor: Intrinsic erythropoietin production in the brain. Kidney Int. 51:416-418.

10 Konishi, Y., Chui, D-H, Hirose, H., Kunishita, T. and Tabira, T. (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 609:29-35.

15 Bernaudin, M., Marti, H.H., Roussel, S., Divoux, D., Nouvelot, A., MacKenzie, E.T. and Petit, E. (1999). A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 19:643-51.

Nakamura, T., Ebihara, I., Shimada, N. and Koide, H. (1998) Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients. Amer. J Med Sci 315:199-201.

20

Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M. and Sasaki, R. (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 269:19488-93.

25 Patent application WO 98-CA991, Weiss, S and Sorokan, S.T. Title: Erythropoietin-mediated neurogenesis.

Campana, W.M., Misasi, R. and O'Brien, J.S. (1998) Identification of a neurotrophic sequence of erythropoietin. Inter. J. Mol. Med. 1:235-241.

30

Patent application: WO 95/03821, O'Brien, J.S., Kishimoto, Y. and Altman, D.E. Title: Prosaposin and cytokine-derived peptides as therapeutic agents.

Konishi, Y., Chui, D-H, Hirose, H., Kunishita, T. and Tabira, T. (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. *Brain Res.* 609:29-35.

5

Mattson, M.P., Barger, S.W., Begley, J, and Mark, R.J. (1994) Calcium, free radicals and excitotoxic neuronal death in primary cell culture. *Methods Cell Biol.* 46:187-216.

Smith-Swintosky VL, Cheo-Isaacs CT, D'Andrea MR, Santulli RJ, Darrow, AL, Andrade-
10 Gordon P. (1997) Protease-activated receptor 2 (PAR-2) is present in the rat hippocampus
and is associated with neurodegeneration. *J. Neurochem.*, 69:1890-1896.

Silva, M., Grillot, D., Benito, A., Richard, C., Nunez, G., Fernandez-Luna, J.L. (1996).
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through
15 Bcl-_{XL} and Bcl-2. *Blood* 88, pp1576-1582.

WHAT IS CLAIMED IS:

1. A method for treating a patient having a condition mediated by neurotoxicity, neurodegeneration or neurological damage, comprising administering to said patient a therapeutically effective amount of a peptide comprising one or more monomeric peptides of 8 to about 40 amino acids in length that bind to EPO receptor, each monomeric peptide comprising a sequence of amino acids $X_4X_5X_aX_bX_6X_cX_dX_7$ (SEQ ID NO: 47), wherein

10 X_a is G or A;

X_b is P or A;

X_c is T or A;

15 X_d is selected from W, A, and F;

X_4 is selected from R, H, Y, L, and W, or X_4 is nonexistent;

20 X_5 is selected from F, M, and I;

X_6 is independently selected from the 20 genetically coded L-amino acids or the stereoisomeric D-amino acids; and

25 X_7 is selected from D, V, E, I, and L.

2. The method of claim 1, wherein said sequence is $X_4X_5GPX_6TWX_7$ (SEQ ID NO: 48).

3. The method of claim 2, wherein said sequence is $X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 30 1), wherein

X_3 is selected from C, E, A, α -amino- γ -bromobutyric acid, and homocysteine (Hoc); and,

X_8 is selected from C, K, A, α -amino- γ -bromobutyric acid, and homocysteine (Hoc).

5. The method of claim 3 with the proviso that either X_3 or X_8 is C or homocysteine (Hoc).

10. The method of claim 4 wherein X_3 or X_8 is C.

15. The method of claim 3 wherein

X_3 is selected from C, E, and A;

15. X_4 is selected from R, H, and Y, or X_4 is nonexistent;

X_6 is selected from V, L, I, M, E, and A; and

20. X_7 is D or V; and

25. X_8 is selected from C, K and A.

7. The method of claim 3 wherein said peptide is a dimer of each of said monomeric peptides comprising a sequence of amino acids Y X_2 X $_3$ X $_4$ X $_5$ GPX $_6$ TWX $_7$ X $_8$ (SEQ ID NO: 2), wherein

25. X_2 and X_6 are each independently selected from the 20 genetically coded L-amino acids;

X_3 is C; and

X_8 is C.

30

8. The method of claim 7 wherein

X₂ is selected from L S H M A and I, or X₂ is nonexistent; and

5 X₆ is selected from V, L, I, M, E, and A.

9. The method of claim 7 wherein each of said monomeric peptides comprises a sequence of amino acids X₁YX₂X₃X₄X₅GPX₆TWX₇X₈X₉X₁₀X₁₁ (SEQ ID NO: 3), wherein each of X₁, X₂, X₆, X₉, X₁₀, and X₁₁ is independently selected from the 20 genetically coded L-amino acids.

10. The peptide dimer of claim 9 wherein

X₃ is selected from C, E, and A;

15 X₄ is selected from R, H, and Y, or X₄ is nonexistent;

X₇ is D or V;

20 X₈ is C or K.

X₉ is K, G, L, Q, R, S, or T; and

X₁₀ is A, G, P, R, or Y.

25 11. The method of Claim 10 wherein

X₁ is D, E, L, N, S, T or V;

30 X₂ is selected from L, S, H, M, A, and I, or X₂ is nonexistent;

X₉ is selected from K, Q, R, S, and G; and

X_{10} is selected from P, Y, and A.

12. The method of claim 3 wherein said peptide is a dimer of each of said monomeric peptides comprising a sequence of amino acids $X'X_2X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 49), wherein X' is selected from D-Tyr, *p*-NO₂-Phe, *p*-NH₂-Phe, *p*-F-Phe, *p*-I-Phe, and 3,5-dibromo-Tyr.

13. The method of claim 12 wherein said sequence is X'CHFGPLTWVC.

10 14. The method of claim 1 wherein each of said monomeric peptides comprise a sequence independently selected from

	GGLYLCRFGPVTWDCGYKGG	(SEQ ID NO:7);
15	GGTYSCHFGPLTWVCKPQGG	(aka EMP-1) (SEQ ID NO:8);
	GGDYHCRMGPLTWVCKPLGG	(SEQ ID NO:9);
	VGNYMCHFGPITWVCRPGGG	(SEQ ID NO:10);
	GGVYACRMGPITWVCSPPLGG	(SEQ ID NO:11);
	VGNYMAHMGPITWVCRPGG	(SEQ ID NO:12);
20	GGTYSCHFGPLTWVCKPQ	(aka EMP-16) (SEQ ID NO:13);
	GGLYACHMGPMTWVCQPLRG	(aka EMP-36) (SEQ ID NO:14);
	TIAQYICYMGPETWECRSPSKA	(aka EMP-38) (SEQ ID NO:15);
	YSCHFGPLTWVCK	(aka EMP-20 (SEQ ID NO:16);
	YCHFGPLTWVC	(aka EMP-23) (SEQ ID NO:17);
25	SCHFGPLTWVCK	(aka EMP-24) (SEQ ID NO:18);
	GGTASCHFGPLTWVCKPQGG	(aka EMP-6) (SEQ ID NO:19);
	GGTYSCHFAPLTWVCKPQGG	(aka EMP-9) (SEQ ID NO:20);
	GGTYSCHFGPLTWVCKPQGG	(aka EMP-27) (SEQ ID NO:21);
	TYSCHFGPLTWVCKPQGG	(aka EMP-17) (SEQ ID NO:22);
30	TYSCHFGPLTWVCKPQ	(aka EMP-18) (SEQ ID NO:23);
	YSCHFGPLTWVCKP	(aka EMP-19) (SEQ ID NO:24);
	YSCHFGPLTWVC	(aka EMP-21) (SEQ ID NO:25);

	YSCHFGALTWVCK	(aka EMP-22) (SEQ ID NO:26);
	GGCRIGPITWVCAGG	(aka EMP-25) (SEQ ID NO:27);
	HFGPLTWV	(aka EMP-26) (SEQ ID NO:28);
	GGTSCHFGPLTWVCKPQGG	(aka EMP-7) (SEQ ID NO:29);
5	GGTFSCHFGPLTWVCKPQGG	(aka EMP-8) (SEQ ID NO:30);
	GGTYSCHFGALTWVCKPQGG	(aka EMP-10) (SEQ ID NO:31);
	GGTYSCHFGPATWVCKPQGG	(aka EMP-11) (SEQ ID NO:32);
	GGTYSCHFGPLAWVCKPQGG	(aka EMP-12) (SEQ ID NO:33);
	GGTYSCHFGPLTAVCKPQGG	(aka EMP-13) (SEQ ID NO:34);
10	GGTYSCHFGPLTFVCKPQGG	(aka EMP-14) (SEQ ID NO:35);
	GGTYSCHFGPLTWVCKAQGG	(aka EMP-15) (SEQ ID NO:36);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-28, X = D-Tyr) (SEQ ID NO:37);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-29, X = <i>p</i> -NO ₂ -Phe)
		(SEQ ID NO:38);
15	GGTXSCHFGPLTWVCKPQGG	(aka EMP-30, X = <i>p</i> -NH ₂ -Phe)
		(SEQ ID NO:39);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-31, X = <i>p</i> -F-Phe) (SEQ ID NO:40);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-32, X = <i>p</i> -I-Phe) (SEQ ID NO:41);
	GGTXSCHFGPLTWVCKPQGG	(aka EMP-33, X = 3,5-dibromo-Tyr)
20		(SEQ ID NO:42);
	Ac-GGTYSCHFGPLTWVCKPQGG	(aka EMP-34) (SEQ ID NO:43);
	GGLYACHMGPMTWVCQPLGG	(aka EMP-35) (SEQ ID NO:44);
	LGRKYSCHFGPLTWVCQPAKKD	(aka EMP-37) (SEQ ID NO:45); and
	GGTYSEHFGPLTWVKKPQGG	(aka EMP-39) (SEQ ID NO:46).
25		
	15. The method of claim 14 wherein each of said monomeric peptides is independently selected from:	
	GGTYSCHFGPLTWVCKPQGG	(aka EMP-1) (SEQ ID NO:8);
	GGTASCHFGPLTWVCKPQGG	(aka EMP-6) (SEQ ID NO:19);
30	GGTYSCHFAPLTWVCKPQGG	(aka EMP-9) (SEQ ID NO:20); and
	YCHFGPLTWVC	(aka EMP-23) (SEQ ID NO:17).

16. The method of claim 1 wherein said peptide is a dimer formed by a polyethylene glycol linker through a covalent bond.
17. The method of claim 16 wherein each monomeric peptides of said dimer are covalently bound N-terminus to N-terminus.
5
18. The method of claim 16 wherein each monomeric peptides of said dimer are covalently bound N-terminus to C-terminus.
- 10 19. The method of claim 1 wherein said monomeric peptides are dimerized on activated benodiazepins, oxazalones, azalactones, aminimides or diketopiperazine.
20. The method of claim 19 wherein said monomeric peptides are covalently bound N-terminus to N-terminus.
15
21. The method of claim 19 wherein said monomeric peptides are covalently bound N-terminus to C-terminus.
22. The peptide of claim 2, which comprises least one peptide dimer.
20
23. A method of activating a cell surface receptor to induce neuroprotective biological activity comprising contacting a dimer of peptides of claim 2 with said receptor thereby inducing said neuroprotective biological activity.
- 25 24. The method of claim 23 wherein said cell surface receptor is contacted with said dimer in vitro or in vivo.
25. The method of claim 23 wherein said cell surface receptor is EPO receptor.
30

26. The method of claim 23 wherein said peptide dimer is a cell surface receptor agonist selected from a group consisting of a GH agonist, PDGF agonist, EGF agonist, G-CSF agonist, TPO (thrombopoietin) agonist, VEGF agonist, FGF agonist, insulin agonist, IL-3 agonist, IL-5 agonist, IL-6 agonist and IL-2 agonist.

5

27. The method of claim 23 wherein said agonist comprises a sequence of amino acids $YX_2X_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 2) wherein each of X_2 and X_6 is independently selected from the 20 genetically coded L-amino acids; X_3 is C; X_4 is R, H, L or W; X_5 is M, F or I; X_7 is D, E, I, L or V; and X_8 is C.

10

28. The method of claim 23 wherein said agonist comprises a sequence of amino acids $X_1YX_2X_3X_4X_5GPX_6TWX_7X_8X_9X_{10}X_{11}$ (SEQ ID NO: 3) wherein each of X_1 , X_2 , X_6 , X_9 , X_{10} , and X_{11} is independently selected from any one of the 20 genetically coded L-amino acids; X_3 is C; X_4 is R, H, L or W; X_5 is M, F or I; X_7 is D, E, I, L or V; and X_8 is C.

15

29. The method of claim 23 wherein said agonist comprises a sequence of amino acids $X_1YX_2X_3X_4X_5GPX_6TWX_7X_8X_9X_{10}X_{11}$ (SEQ ID NO: 3) wherein each of X_1 , X_2 , and X_{11} , is independently selected from any one of the 20 genetically coded L-amino acids; X_3 is C; X_4 is R or H; X_5 is F or M; X_6 is I, L, T, M or V; X_7 is D or V; X_9 is G, K, L, Q, R, S, or T; and X_{10} is A, G, P, R, or Y.

20

30. The method of claim 23 wherein said agonist comprises a sequence of amino acids $X_1YX_2X_3X_4X_5GPX_6TWX_7X_8X_9X_{10}X_{11}$ (SEQ ID NO: 3) wherein X_1 is D, E, L, N, S, T or V; X_2 is A, H, K, L, M, S, or T; X_3 is C; X_4 is R or H; X_5 is M, F or I; X_6 and X_{11} are independently any one of the 20 genetically coded L- amino acids; X_7 is D, E, I, L or V; X_8 is C; X_9 is K, R, S, or T; and X_{10} is P.

25

30

31. The method of claim 23 wherein said agonist is selected from a group consisting of:

	GGLYLCRFGPVTWDCGYKGG	(SEQ ID NO:7);
	GGTYSCHFGPLTWVCKPQGG	(aka EMP-1) (SEQ ID NO:8);
5	GGDYHCRMGPLTWVCKPLGG	(SEQ ID NO:9);
	VGNYMCHFGPITWVCRPGGG	(SEQ ID NO:10);
	GGVYACRMGPITWVCSPPLGG	(SEQ ID NO:11);
	VGNYMAHMGPITWVCRPGG	(SEQ ID NO:12);
	GGTYSCHFGPLTWVCKPQ	(aka EMP-16) (SEQ ID NO:13);
10	GGLYACHMGPMTWVCQPLRG	(aka EMP-36) (SEQ ID NO:14);
	TIAQYICYMGPETWECRSPSKA	(aka EMP-38) (SEQ ID NO:15);
	YSCHFGPLTWVCK	(aka EMP-20) (SEQ ID NO:16);
	YCHFGPLTWVC	(aka EMP-23) (SEQ ID NO:17);
	SCHFGPLTWVCK	(aka EMP-24) (SEQ ID NO:18);
15	GGTASCHFGPLTWVCKPQGG	(aka EMP-6) (SEQ ID NO:19);
	GGTYSCHFAPLTWVCKPQGG	(aka EMP-9) (SEQ ID NO:20);
	GGTYSCHFGPLTWVCKPQGG	(aka EMP-27) (SEQ ID NO:21);
	TYSCHFGPLTWVCKPQGG	(aka EMP-17) (SEQ ID NO:22);
	TYSCHFGPLTWVCKPQ	(aka EMP-18) (SEQ ID NO:23);
20	YSCHFGPLTWVCKP	(aka EMP-19) (SEQ ID NO:24);
	YSCHFGPLTWVC	(aka EMP-21) (SEQ ID NO:25);
	YSCHFGALTWVCK	(aka EMP-22) (SEQ ID NO:26);
	GGCRIGPITWVC CGG	(aka EMP-25) (SEQ ID NO:27);
	HFGPLTWV	(aka EMP-26) (SEQ ID NO:28);
25	GGTSCHFGPLTWVCKPQGG	(aka EMP-7) (SEQ ID NO:29);
	GGTFSCHFGPLTWVCKPQGG	(aka EMP-8) (SEQ ID NO:30);
	GGTYSCHFGALTWVCKPQGG	(aka EMP-10) (SEQ ID NO:31);
	GGTYSCHFGPATWVCKPQGG	(aka EMP-11) (SEQ ID NO:32);
	GGTYSCHFGPLAWVCKPQGG	(aka EMP-12) (SEQ ID NO:33);
30	GGTYSCHFGPLTAVCKPQGG	(aka EMP-13) (SEQ ID NO:34);
	GGTYSCHFGPLTFVCKPQGG	(aka EMP-14) (SEQ ID NO:35);
	GGTYSCHFGPLTWVCKAQGG	(aka EMP-15) (SEQ ID NO:36);

GGTXSCHFGPLTWVCKPQGG	(aka EMP-28, X = D-Tyr) (SEQ ID NO:37);
GGTXSCHFGPLTWVCKPQGG	(aka EMP-29, X = <i>p</i> -NO ₂ -Phe) (SEQ ID NO:38);
GGTXSCHFGPLTWVCKPQGG	(aka EMP-30, X = <i>p</i> -NH ₂ -Phe) (SEQ ID NO:39);
GGTXSCHFGPLTWVCKPQGG	(aka EMP-31, X = <i>p</i> -F-Phe) (SEQ ID NO:40);
GGTXSCHFGPLTWVCKPQGG	(aka EMP-32, X = <i>p</i> -I-Phe) (SEQ ID NO:41);
GGTXSCHFGPLTWVCKPQGG	(aka EMP-33, X = 3,5-dibromo-Tyr) (SEQ ID NO:42);
Ac-GGTYSCHFGPLTWVCKPQGG	(aka EMP-34) (SEQ ID NO:43);
GGLYACHMGPMTWVCQPLGG	(aka EMP-35) (SEQ ID NO:44);
LGRKYSCHFGPLTWVCQPAKKD	(aka EMP-37) (SEQ ID NO:45); and
GGTYSEHFGPLTWVKKPQGG	(aka EMP-39) (SEQ ID NO:46).

15 32. The method of claim 23 wherein said peptide dimers are formed with a polyethylene glycol linker through a covalent bond.

33. A method of preparing a cell surface receptor agonist comprising dimerizing a cell surface antagonist.

20 34. The method of claim 33 wherein said cell surface antagonist receptor is a GH antagonist, PDGF antagonist, EGF antagonist, G-CSF antagonist, EGF antagonist, GM-CSF antagonist, TPO antagonist, VEGF antagonist, FGF antagonist, insulin antagonist, IL-3 antagonist, IL-5 antagonist, IL-6 antagonist, or an IL-2 antagonist.

25 35. The method of claim 33 wherein said cell surface receptor antagonist is an EPO-R antagonist.

30 36. The method of claim 35 wherein said antagonist comprises a sequence of amino acids $(X?X_2)_nX_3X_4X_5GPX_6TWX_7X_8$ (SEQ ID NO: 19) wherein X_6 is selected from the genetically coded L-amino acids; X_3 is C; X_4 is R, H, L or W; X_5 is M, F or I; X_7 , is

D, E, I, L or V; X₈ is C; X₂ is selected from the 20 genetically coded L-amino acids, n is 0 or 1 and X? is any of the 20 genetically coded L-amino acids except Y (tyrosine).

37. The method of Claim 33 where said antagonist is SCHFGPLTWVCK
5 (SEQ ID NO: 18).




FIGURE 1A**RAT CEREBRAL CORTICAL CULTURES EXPRESS EPO RECEPTOR****1dic Negative Control****3dic Negative Control****7dic Negative Control****1dic EBP-7 Antibody****3dic EBP-7 Antibody****7dic EBP-7 Antibody**



FIGURE 1BRAT HIPPOCAMPAL CULTURES EXPRESS EPO RECEPTOR**1dic Negative Control****3dic Negative Control****7dic Negative Control****1dic EBP-7 Antibody****3dic EBP-7 Antibody****7dic EBP-7 Antibody**

FIGURE 2

EPO RECEPTOR IS EXPRESSED ON PC12 AND SK-N-MC CELLS






FIGURE 3EPO INDUCED GENE EXPRESSION IN PC12 CELLS


Erythropoietin regulates the expression of the BCL family members Bcl_{XL} and Bak.

FIGURE 4

**EPO PROTECTS RAT CEREBRAL CORTICAL CELLS FROM
GLUTAMATE TOXICITY**




t-test (one-tailed) comparison between treatments * p<0.01; ** p<0.001

FIGURE 5**EPO PROTECTS PC12 CELLS FROM GLUTAMATE-INDUCED CELL DEATH**

Erythropoietin protects PC-12 cells from glutamate mediated cytotoxicity.

FIGURE 6


EPO PROTECTS PC12 CELLS FROM NGF WITHDRAWAL-INDUCED
CELL DEATH




**Erythropoietin protects PC-12 cells against death induced
by NGF withdrawal.**

FIGURE 7

EPO PROMOTES NEURITE OUTGROWTH IN RAT CEREBRAL
CORTICAL CULTURES



One-way ANOVA comparison between groups $p<0.0001$;
Dunnett's multiple comparison test $p>0.05$, ns
unpaired t-test (one-way) * $p<0.05$; ** $p<0.01$, *** $p<0.001$

FIGURE 8**EPO PROMOTES NEURITE OUTGROWTH IN RAT HIPPOCAMPAL CULTURES**

**One-way ANOVA comparison between treatment groups $p<0.0001$;
Dunnett's multiple comparison test $*p<0.01$;
unpaired t-test (one-tailed) $***p<0.001$; + $p<0.0001$**

FIGURE 9

EMP-1 PROMOTES NEURITE OUTGROWTH IN RAT CEREBRAL
CORTICAL CULTURES





FIGURE 10EMP-1 PROMOTES NEURITE OUTGROWTH IN RAT HIPPOCAMPAL CULTURES


FIGURE 11**EMP-6 PROMOTES NEURITE OUTGROWTH IN RAT CEREBRAL
CORTICAL CULTURES**


FIGURE 12**EMP-6 PROMOTES NEURITE OUTGROWTH IN RAT HIPPOCAMPAL CULTURES**


FIGURE 13**EMP-9 PROMOTES NEURITE OUTGROWTH IN RAT CEREBRAL
CORTICAL CULTURES**


FIGURE 14**EMP-9 PROMOTES NEURITE OUTGROWTH IN RAT HIPPOCAMPAL CULTURES**


FIGURE 15**EMP-23 PROMOTES NEURITE OUTGROWTH IN RAT CEREBRAL
CORTICAL CULTURES**

FIGURE 16

EMP-23 PROMOTES NEURITE OUTGROWTH IN RAT
HIPPOCAMPAL CULTURES




FIGURE 17

EMP-27 PROMOTES NEURITE OUTGROWTH IN RAT CEREBRAL
CORTICAL CULTURES




FIGURE 18

EMP-27 PROMOTES NEURITE OUTGROWTH IN RAT
HIPPOCAMPAL CULTURES





FIGURE 19

STUDY I: EPO PROTECTS AGAINST ISCHEMIC INJURY BY CONTINUOUS INTRAVENOUS INFUSION VIA OSMOTIC MINI-PUMP



One-way ANOVA comparison between treatments $p=0.01$
t-test (one-tailed) comparison between treatments * $p\leq 0.01$

FIGURE 20

STUDY I: PLASMA DETERMINATIONS





FIGURE 21

**STUDY II: EPO DOES NOT PROTECT AGAINST ISCHEMIC INJURY WHEN
ADMINISTERED AS A SINGLE INTRAVENOUS BOLUS**



One-way ANOVA comparison between treatment groups; $p>0.05$, n.s.




FIGURE 22**STUDY II: PLASMA DETERMINATIONS**

FIGURE 23**STUDY III: EPO PROTECTS AGAINST ISCHEMIC INJURY VIA REPEAT
INTRAVENOUS BOLUS DOSING**

One-way ANOVA comparison between treatment groups $p=0.02$
Dunnett's multiple comparison t-test * $p<0.05$

FIGURE 24**STUDY III: PLASMA DETERMINATIONS****Study III: Plasma Concentration**

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/16654

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 38/00; C07K 2/00, 5/00, 7/00

US CL :514/12, 13, 14, 15; 530/300, 324, 326, 345

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 13, 14, 15; 530/300, 324, 326, 345

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,767,078 A (JOHNSON et al) 16 June 1998, Abstract, col. 2, lines 21-42, and col. 5, lines 13-30.	33-35



Further documents are listed in the continuation of Box C.



See patent family annex.

• Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
07 SEPTEMBER 2001

Date of mailing of the international search report

22 OCT 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3290Authorized officer
ABDEL A. MOHAMMED
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/16654

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-32 and 36-37
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

The CRF for this application is defective. Claims 1-32 and 36-37 recite SEQ ID NOS:1-47 or they depend therefrom, and as such, they are unsearchable.

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/16654

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAS ONLINE, DIALOG, MEDLINE, EMBASE, BIOSIS, WPIDS

search terms: Erythropoietin or EPO, erythropoietin receptor or EPO-R, peptide or polypeptide, dimer or monomer, cytokine, growth hormone or GH, neuroprotect? or neurotherapeut? or neurotox? or neurodegenerat? hematopo?

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.